Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | ey57a | — |
Early dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 49-year-old female patient who received HAV (Havrix) (batch number ey57a, expiry date 13-OCT-2026) for prophylaxis. Previously administered products included Havrix (Received 1st dose of Havrix vaccine on 10-APR-2025 (batch number 772YT)). On 27-SEP-2025, the patient received the 2nd dose of Havrix. On 27-SEP-2025, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: Early dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 05-NOV-2025 and 06-NOV-2025 The patient received Havrix injection on 10 April and then they received their 2nd one on 27 September which is 2 weeks early. The reporter was trying to contact to see if that was still okay, still valid dose. Technically it wasn't 6 months early and it diddnt qualify in the 4 days early that usually the talks about. The patient wanted to know if she need to be revaccinated and if she should revaccinate, should she be revaccinated now since it's been 6 months or she should revaccinate 6 months from her 2nd dose.